ASX · MEM.AX
Memphasys Limited
A$0.00-A$0.00 (-11.11%)
Memphasys Limited’s quoted price sits in the lower half of its reported 52-week range, 55.56% below the high.
Loading market information…
ASX · VBS.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 01:28 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Vectus Biosystems Limited’s quoted price sits in the lower half of its reported 52-week range, 83.52% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vectus Biosystems Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.00-A$0.00 (-11.11%)
Memphasys Limited’s quoted price sits in the lower half of its reported 52-week range, 55.56% below the high.
A$0.10A$0.00 (0.0%)
Invex Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 33.33% below the high.
A$0.03A$0.00 (0.0%)
InhaleRx Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
A$0.01-A$0.00 (0.0%)
Acrux Limited’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
A$0.04-A$0.00 (-5.41%)
Invion Limited’s quoted price sits in the lower half of its reported 52-week range, 68.18% below the high.
A$0.01+A$0.00 (+7.69%)
Bio-Gene Technology Limited’s quoted price sits in the lower half of its reported 52-week range, 71.43% below the high.
A$0.01A$0.00 (0.0%)
Cann Group Limited’s quoted price sits in the lower half of its reported 52-week range, 61.54% below the high.
A$0.00-A$0.00 (-25.0%)
HITIQ Limited’s quoted price sits in the lower half of its reported 52-week range, 92.5% below the high.
